Tech Company Financing Transactions

Candel Therapeutics Funding Round

Northpond Ventures, H7 Holdings and Level One Partners participated in a $22.5 million Series C venture round for Candel Therapeutics. The round was announced by the company on 4/2/2019.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

117 Kendrick St. 450
Needham, MA 02494
USA

Phone

(617) 916-5445

Website

www.candeltx.com

Email Address

[email protected]

Overview

Candel Therapeutics is a Massachusetts based biotechnology company developing our proprietary immuno-oncology platforms, including they are Gene Mediated Cytotoxic Immunotherapy (GMCI�) platform and our rQNestin34.5 platform for the treatment of solid tumors.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Estuardo Aguilar-Cordova

        

Chief Medical Officer

Laura Aguilar

        

VP - Bus. Development

Brian Guzik

        

VP - Bus. Development

Stephen Rocamboli

        

VP - Manufacturing

Daniel Giroux

        

VP - R & D

Andrea Manzanera

        

Browse more venture capital transactions:

Prev: 4/2/2019: Agorize venture capital transaction
Next: 4/2/2019: Karuna Therapeutics venture capital transaction

Share this article

About Our VC Transactions Data

We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary